5 hasil untuk "L. Forlani"
Menampilkan 1–5 · 0,23 detik · RSS
-
Artikel Jurnal
DP025 | INDUCTION THERAPY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: INNOVATIONS IN THE ERA OF HYPOMETHYLATING AGENTS AND VENETOCLAX COMBINATION THERAPY
Background Prior to the approval of hypomethylating agents (HMAs) in combination with venetoclax (Ven) as first-line therapy for newly diagnosed Acute Myeloid Leukemia (AML) in 2017, intensive chemotherapy (ICT) was the only viable option for achieving remission in fit elderly patients. However…
-
Artikel Jurnal
P066 | FACTORS INFLUENCING MOLECULAR RELAPSE IN FAVORABLE-RISK, INTENSIVELY-TREATED, NPM1-MUTATED ACUTE MYELOID LEUKEMIA
As per 2021 ELN guidelines, for NPM1-mutated AML patients only the end-of-treatment (EOT) MRD is considered a clinically relevant biomarker, with thresholds of qPCR NPM1mut/ABL1% >2% (hereafter defined as NPM1%) and logarithmic reduction relative to diagnosis 2% or LogR2% or LogR2.1% was observed…
-
Artikel Jurnal
P057 | HYPERLEUKOCYTOSIS AND EXTRAMEDULLARY INVOLVEMENT IN ACUTE MYELOID LEUKEMIA: THE ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Background Newly diagnosed cases of Acute Myeloid Leukemia (AML) are stratified according to the 2022 European LeukemiaNet (ELN) recommendations based on their cytogenetic and molecular profiles. However, the literature suggests that hyperleukocytosis (HL) and extramedullary involvement (EI) may…
-
Artikel Jurnal
DP020 | CLINICAL-BIOLOGICAL CHARACTERISTICS AND TREATMENT MODULATION IN AML PATIENTS RECEIVING LONG-TERM (>24 COURSES) TREATMENT WITH HYPOMETHYLATING AGENTS AND VENETOCLAX.
INTRODUCTION. Venetoclax (VEN) in combination with hypomethylating agents (VEN+HMAs) has become the treatment of choice for patients (pts) with AML who are ineligible for IC . The primary goal of this combination is to prolong survival (OS) maintaining a good quality of life. To date, no specific…
-
Artikel Jurnal
DP083 | THE IMPACT OF FLT3-TKD MUTATION IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA PATIENTS: A RETROSPECTIVE SUBANALYSIS OF A LARGE MULTICENTRIC ITALIAN COHORT
According to the current European Leukemia Network guidelines (ELN 2022), FLT3-TKD mutation is no longer included in the risk classification and NPM1mut FLT3-TKDmut AML patients (pts) without high risk cytogenetics are in the favorable-risk group. The aim of the study was to evaluate, in a…